Summary

The market for transplant diagnostics is valued at around USD 5.61 billion in 2026 and is expected to reach USD 8.14 billion by 2031, at a growth rate of 7.8%. The growing number of organ transplantation procedures is driving the demand for various testing methods, including donor-recipient compatibility testing, histocompatibility testing, infectious disease testing, and blood profiling. Additionally, the rising adoption of molecular diagnostic technologies, such as PCR (polymerase chain reaction) and NGS (next-generation sequencing), is further fueling market growth. These technologies offer advantages such as high procedural efficacy, quick turnaround times, and real-time sample analysis. Furthermore, increasing awareness of the benefits of molecular diagnostic techniques in reducing the risk of graft rejection and improving transplantation outcomes is also contributing to market expansion.

“The diagnostic applications segment is expected to witness the fastest growth rate in the transplant diagnostics market, by application, during the forecast period.”
Based on application, the transplant diagnostics market is divided into diagnostic applications and research applications. In 2025, the diagnostic applications segment is expected to experience the fastest growth in the transplant diagnostics market. This growth is primarily due to advancements in molecular assay techniques and the increasing use of these procedures for pathogen detection and histocompatibility testing. Additionally, the rising incidence of chronic diseases that require transplantation is boosting demand for transplant diagnostic products and services. There is also a greater risk of genetic disorders and pathogen infections following transplantation, which supports the need for effective donor-recipient compatibility testing and post-transplant monitoring. Furthermore, growing awareness of the importance of accurate transplant diagnostics in reducing the risks of graft rejection and improving transplantation outcomes is contributing to the expansion of this segment.

“The solid organ transplantation segment accounted for the largest market share in the transplant diagnostics market, by type, in 2025.”
Based on transplant type, the transplant diagnostics market is divided into solid organ transplantation, stem cell transplantation, soft tissue transplantation, and bone marrow transplantation. In 2025, the solid organ transplantation segment led the transplant diagnostics market. This segment's significant share is mainly due to the growing use of transplant diagnostic products for various purposes, including donor-recipient compatibility testing, infectious disease testing, histocompatibility testing, genomic profiling, and blood profiling during solid organ transplantation procedures. Moreover, the increasing number of organ transplantation procedures, supportive government regulations, the rising prevalence of chronic diseases and disorders requiring transplantation, and technological advancements in transplant diagnostics are further contributing to the growth of this segment.

“The Asia Pacific is the fastest-growing market for transplant diagnostics during the forecast period.”
Based on region, the transplant diagnostics market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2025, the Asia Pacific region is expected to see the fastest growth in the transplant diagnostics market. This growth is primarily driven by increased healthcare spending, rapid advances in healthcare infrastructure, greater adoption of advanced diagnostic technologies, and significant economic growth in emerging Asia-Pacific countries. Additionally, factors such as a rising elderly population, an increased prevalence of chronic diseases requiring transplants, and growing government initiatives to modernize healthcare systems in countries like China, India, and Japan are further supporting market expansion. Furthermore, Japan's provision of universal healthcare coverage for transplantation-related procedures and the burgeoning medical tourism industry across Asia Pacific countries are also contributing to the growth of the transplant diagnostics market in the region.

The breakup of the profile of primary participants in the transplant diagnostics market:
・By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
・By Designation: C-level Executives (27%), Directors (18%), and Other Designations (55%)
・By Region: North America (51%), Europe (21%), Asia Pacific (18%), Latin America (6%), and the Middle East & Africa (4%)
The key players in the molecular infectious disease testing market are Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Netherlands), bioMérieux (France), Becton, Dickinson and Company (US), Illumina, Inc. (US), DiaSorin S.p.A. (Italy), CAREDX, INC. (US), Werfen (Spain), Hologic, Inc. (US), Merck KGaA (Germany), Eurobio Scientific (France), Biofortuna Limited (UK), BAG Diagnostics GmbH (Germany), Fujirebio (Japan), HistoGenetics LLC (US), PacBio (US), TBG Biotechnology Corp (Taiwan), Scisco Genetics, Inc. (US), inno-train Diagnostik GmbH (Germany), Bionobis (France), Takara Bio Inc. (Japan), Krishgen Biosystems Private Limited (India), and Prolmmune Ltd. (UK).

Research Coverage:
This research report categorizes the transplant diagnostics market by product & service (reagents & consumables, instruments, and software & services), technology {molecular assays [PCR-based molecular assays (real-time PCR, sequence-specific primer-PCR, sequence-specific oligonucleotide-PCR, and other PCR-based molecular assays), sequencing-based molecular assays (Sanger sequencing, next-generation sequencing, and other sequencing-based molecular assays)] and non-molecular assays}, application {diagnostic applications [pre-transplantation diagnostics (infectious disease testing, histocompatibility testing, and blood profiling) and post-transplantation diagnostics] and research applications}, transplant type [solid organ transplantation (kidney transplantation, liver transplantation, heart transplantation, lung transplantation, pancreas transplantation, and other organ transplantation), stem cell transplantation, soft tissue transplantation, and bone marrow transplantation], end user (hospitals & transplant centers, research & academic institutes, and independent reference laboratories), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). This report provides a comprehensive overview of the key factors driving growth in the transplant diagnostics market, including drivers, restraints, opportunities, and challenges. It offers an in-depth analysis of the major industry players, highlighting their business models, available solutions, key strategies, recent acquisitions, and agreements. Additionally, the report includes a competitive analysis of emerging startups in the transplant diagnostics market.
Reasons to Buy this Report:
The report will assist market leaders and new entrants in the transplant diagnostics industry by providing estimated revenue figures for the overall market and its subsegments. It aims to help stakeholders understand the competitive landscape, allowing them to position their businesses more effectively and develop appropriate go-to-market strategies. Additionally, the report offers insights into the market dynamics, including key drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
・Analysis of key drivers (increasing number of transplant procedures, advancements in molecular diagnostic technologies, increasing public-private funding for transplant research, and rising prevalence of infectious diseases), restraints (high cost of advanced molecular diagnostic techniques and limited access to advanced transplant diagnostic infrastructure in emerging economies), opportunities (increasing adoption of cross-matching and chimerism testing and growing awareness regarding organ donation and transplantation), and challenges (gap between organ donor availability and transplant demand) influencing the growth of the transplant diagnostics market.
・Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the transplant diagnostics market.
・Market Development: Comprehensive information about lucrative markets; the report analyzes the transplant diagnostics market across varied regions.
・Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the transplant diagnostics market.
・Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Netherlands), and bioMérieux (France).

ページTOPに戻る

Table of Contents

1 INTRODUCTION 41
1.1 STUDY OBJECTIVES 41
1.2 MARKET DEFINITION 41
1.3 STUDY SCOPE 42
1.3.1 MARKETS COVERED & REGIONAL SCOPE 42
1.3.2 INCLUSIONS & EXCLUSIONS 43
1.3.3 YEARS CONSIDERED 44
1.4 CURRENCY CONSIDERED 44
1.5 STAKEHOLDERS 44
1.6 SUMMARY OF CHANGES 45
2 EXECUTIVE SUMMARY 46
2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 46
2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS 47
2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH 48
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 49
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 50
3 PREMIUM INSIGHTS 51
3.1 TRANSPLANT DIAGNOSTICS MARKET OVERVIEW 51
3.2 TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2026 VS. 2031 52
3.3 TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2026 VS. 2031 52
3.4 TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2026 VS. 2031 53
3.5 TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2026 VS. 2031 53
3.6 TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2026 VS. 2031 54
3.7 TRANSPLANT DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 54
4 MARKET OVERVIEW 55
4.1 INTRODUCTION 55
4.2 MARKET DYNAMICS 56
4.2.1 DRIVERS 56
4.2.1.1 Increasing number of transplant procedures 56
4.2.1.2 Advancements in molecular diagnostic technologies 57
4.2.1.3 Increasing public-private funding for transplant research 58
4.2.1.4 Rising incidence of chronic diseases 59
4.2.2 RESTRAINTS 59
4.2.2.1 High cost of instruments and consumables 59
4.2.2.2 Limited access to advanced transplant diagnostic infrastructure in emerging economies 60
4.2.3 OPPORTUNITIES 61
4.2.3.1 Increasing adoption of cross-matching and chimerism testing 61
4.2.3.2 Growing awareness regarding organ donation and transplantation 61
4.2.4 CHALLENGES 62
4.2.4.1 Gap between organ donor availability and transplant demand 62
4.3 UNMET NEEDS & WHITE SPACES 63
4.3.1 UNMET NEEDS IN TRANSPLANT DIAGNOSTICS MARKET 63
4.3.2 WHITE SPACE OPPORTUNITIES 64
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 65
4.4.1 INTERCONNECTED MARKETS 65
4.4.2 CROSS-SECTOR OPPORTUNITIES 66
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 67
4.5.1 KEY MOVES & STRATEGIC FOCUS 67
5 INDUSTRY TRENDS 68
5.1 PORTER’S FIVE FORCES ANALYSIS 68
5.1.1 BARGAINING POWER OF SUPPLIERS 69
5.1.2 BARGAINING POWER OF BUYERS 69
5.1.3 THREAT OF NEW ENTRANTS 69
5.1.4 THREAT OF SUBSTITUTES 70
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 70
5.2 MACROECONOMIC INDICATORS 70
5.2.1 INTRODUCTION 70
5.2.2 GDP TRENDS & FORECAST 70
5.3 SUPPLY CHAIN ANALYSIS 74
5.4 VALUE CHAIN ANALYSIS 75
5.5 ECOSYSTEM ANALYSIS 77
5.6 PRICING ANALYSIS 78
5.6.1 AVERAGE SELLING PRICE TREND OF TRANSPLANT DIAGNOSTIC PRODUCTS, BY KEY PLAYER, 2024–2026 78
5.6.2 AVERAGE SELLING PRICE TREND OF TRANSPLANT DIAGNOSTIC PRODUCTS, BY REGION, 2024–2026 79
5.7 TRADE ANALYSIS 81
5.7.1 IMPORT SCENARIO (HS CODE 3822) 81
5.7.2 EXPORT SCENARIO (HS CODE 3822) 82
5.8 KEY CONFERENCES & EVENTS, 2026–2027 83
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 84
5.10 INVESTMENT & FUNDING SCENARIO 84
5.11 IMPACT OF 2025 US TARIFFS ON TRANSPLANT DIAGNOSTICS MARKET 85
5.11.1 INTRODUCTION 85
5.11.2 KEY TARIFF RATES 85
5.11.3 PRICE IMPACT ANALYSIS 86
5.11.4 IMPACT ON REGION 86
5.11.4.1 North America 87
5.11.4.2 Europe 87
5.11.4.3 Asia Pacific 87
5.11.5 IMPACT ON END-USE INDUSTRIES 88
5.11.5.1 Hospitals & transplant centers 88
5.11.5.2 Research & academic institutes 88
5.11.5.3 Independent reference laboratories 88
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 89
6.1 KEY EMERGING TECHNOLOGIES 89
6.1.1 DONOR-DERIVED CELL-FREE DNA (DD-CFDNA) 89
6.1.2 DIGITAL PCR (DPCR) 89
6.2 COMPLEMENTARY TECHNOLOGIES 90
6.2.1 AI IN TRANSPLANT DIAGNOSTICS 90
6.2.2 BIOINFORMATICS 90
6.3 ADJACENT TECHNOLOGIES 91
6.3.1 LIQUID BIOPSY 91
6.3.2 DIGITAL PATHOLOGY 91
6.4 TECHNOLOGY/PRODUCT ROADMAP 92
6.5 PATENT ANALYSIS 94
6.5.1 LIST OF KEY PATENTS 95
6.6 FUTURE APPLICATIONS 96
6.7 IMPACT OF AI/GENERATIVE AI ON TRANSPLANT DIAGNOSTICS MARKET 97
6.7.1 INTRODUCTION 97
6.7.2 TOP USE CASES & MARKET POTENTIAL 98
6.7.3 KEY COMPANIES IMPLEMENTING AI 98
6.7.4 FUTURE OF AI 99
7 SUSTAINABILITY & REGULATORY LANDSCAPE 100
7.1 REGIONAL REGULATIONS & COMPLIANCE 100
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 100
7.2 SUSTAINABILITY INITIATIVES 102
7.2.1 ENVIRONMENTAL IMPACT & ECO-FRIENDLY INITIATIVES IN TRANSPLANT DIAGNOSTICS 102
7.2.1.1 Eco-friendly initiatives 103
7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 103
 
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 105
8.1 DECISION-MAKING PROCESS 105
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 105
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 105
8.2.2 BUYING CRITERIA 106
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 107
8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 108
8.5 MARKET PROFITABILITY 110
8.5.1 REVENUE POTENTIAL 110
8.5.2 COST DYNAMICS 110
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 111
9 TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES 112
9.1 INTRODUCTION 113
9.2 REAGENTS & CONSUMABLES 113
9.2.1 REAGENTS & CONSUMABLES TO BE LARGEST AND FASTEST-GROWING SEGMENT IN TRANSPLANT DIAGNOSTICS MARKET 113
9.3 INSTRUMENTS 116
9.3.1 INCREASING PUBLIC-PRIVATE INVESTMENTS TO DRIVE MARKET 116
9.4 SOFTWARE & SERVICES 119
9.4.1 GROWING AUTOMATION & DIGITALIZATION OF DIAGNOSTIC LABORATORY PROCEDURES TO SUPPORT MARKET GROWTH 119
10 TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY 123
10.1 INTRODUCTION 124
10.2 MOLECULAR ASSAYS 124
10.2.1 PCR-BASED MOLECULAR ASSAYS 128
10.2.1.1 Real-time PCR 132
10.2.1.1.1 Smaller sample volume requirements compared to conventional PCR technologies to drive demand 132
10.2.1.2 Sequence-specific primer-PCR (SSP-PCR) 135
10.2.1.2.1 Growing public-private investments for research activities to support market growth 135
10.2.1.3 Sequence-specific oligonucleotide-PCR (SSO-PCR) 138
10.2.1.3.1 Wide adoption of technique in PCR-based molecular assays market to fuel growth 138
10.2.1.4 Other PCR-based molecular assays 141
10.2.2 SEQUENCING-BASED MOLECULAR ASSAYS 144
10.2.2.1 Sanger sequencing 148
10.2.2.1.1 Growing demand for high-throughput DNA sequencers in transplant diagnostic applications to drive market 148
10.2.2.2 Next-generation sequencing (NGS) 151
10.2.2.2.1 Low turnaround time and high-throughput sequencing to drive adoption of NGS 151
10.2.2.3 Other sequencing-based molecular assays 154
10.3 NON-MOLECULAR ASSAYS 157
10.3.1 REPLACEMENT OF NON-MOLECULAR ASSAY TECHNIQUES WITH DNA-BASED TECHNIQUES TO HAMPER GROWTH 157
11 TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION 161
11.1 INTRODUCTION 162
11.2 DIAGNOSTIC APPLICATIONS 162
11.2.1 PRE-TRANSPLANTATION DIAGNOSTICS 166
11.2.1.1 Infectious disease testing 169
11.2.1.1.1 Growing adoption of advanced molecular techniques for pathogen detection to drive market 169
11.2.1.2 Histocompatibility testing 172
11.2.1.2.1 Technological advancements and growing R&D activities to propel market 172
11.2.1.3 Blood profiling 175
11.2.1.3.1 Growing availability of molecular assay products to support market growth 175
11.2.2 POST-TRANSPLANTATION DIAGNOSTICS 178
11.2.2.1 Greater risk of disorders and infections post-transplantation to make diagnostics necessary step 178
11.3 RESEARCH APPLICATIONS 181
11.3.1 GROWING FUNDING FOR RESEARCH TO DRIVE MARKET 181
12 TRANSPLANT DIAGNOSTICS MARKET, BY TYPE 185
12.1 INTRODUCTION 186
12.2 SOLID ORGAN TRANSPLANTATION 186
12.2.1 KIDNEY TRANSPLANTATION 190
12.2.1.1 Rising prevalence of kidney diseases to drive market 190
12.2.2 LIVER TRANSPLANTATION 193
12.2.2.1 Growing patient population with chronic liver diseases and increasing procedural volume to drive market 193
12.2.3 LUNG TRANSPLANTATION 196
12.2.3.1 Rising prevalence of chronic lung diseases to drive market 196
12.2.4 HEART TRANSPLANTATION 199
12.2.4.1 Increasing prevalence of chronic cardiac diseases to propel market 199
12.2.5 PANCREAS TRANSPLANTATION 202
12.2.5.1 Procedural complexity and risk of surgical complications to restrain growth 202
12.2.6 OTHER SOLID ORGAN TRANSPLANTATION 205
12.3 STEM CELL TRANSPLANTATION 208
12.3.1 RISING PROCEDURAL VOLUME AND GROWING RESEARCH ACTIVITIES TO DRIVE MARKET 208
 
12.4 SOFT TISSUE TRANSPLANTATION 211
12.4.1 TECHNOLOGICAL ADVANCEMENTS AND RISING PREVALENCE OF TARGET DISEASES TO DRIVE MARKET 211
12.5 BONE MARROW TRANSPLANTATION 214
12.5.1 DEARTH OF WELL-TRAINED SURGEONS TO PERFORM BONE MARROW TRANSPLANTATION TO HINDER GROWTH 214
13 TRANSPLANT DIAGNOSTICS MARKET, BY END USER 218
13.1 INTRODUCTION 219
13.2 INDEPENDENT REFERENCE LABORATORIES 219
13.2.1 RISING CONSOLIDATION OF DIAGNOSTIC LABORATORIES TO DRIVE MARKET 219
13.3 HOSPITALS & TRANSPLANT CENTERS 222
13.3.1 GROWING PURCHASING POWER OF HOSPITALS & TRANSPLANT CENTERS TO SUPPORT MARKET GROWTH 222
13.4 RESEARCH LABORATORIES & ACADEMIC INSTITUTES 225
13.4.1 INCREASING INDUSTRY-ACADEMIA COLLABORATIONS IN GENOMICS-BASED TRANSPLANT DIAGNOSTIC RESEARCH TO DRIVE MARKET 225
14 TRANSPLANT DIAGNOSTICS MARKET, BY REGION 230
14.1 INTRODUCTION 231
14.2 NORTH AMERICA 231
14.2.1 US 238
14.2.1.1 Growing organ transplantation activity to support market expansion 238
14.2.2 CANADA 243
14.2.2.1 Growing transplant programs to support market growth 243
14.3 EUROPE 248
14.3.1 GERMANY 254
14.3.1.1 Expanding donor registry network to fuel market growth 254
14.3.2 UK 259
14.3.2.1 Rising transplant demand to support market growth 259
14.3.3 FRANCE 264
14.3.3.1 Growing organ donation initiatives to drive growth 264
14.3.4 ITALY 269
14.3.4.1 Increasing organ donation rates to drive market growth 269
14.3.5 SPAIN 274
14.3.5.1 Strong organ donation system to support market growth 274
14.3.6 REST OF EUROPE 279
14.4 ASIA PACIFIC 284
14.4.1 CHINA 291
14.4.1.1 Expanding transplantation programs to drive market growth 291
14.4.2 JAPAN 296
14.4.2.1 Growing transplant waiting population to support market growth 296
 
14.4.3 INDIA 301
14.4.3.1 Rising transplant procedures to drive market growth 301
14.4.4 AUSTRALIA 306
14.4.4.1 Rising number of solid organ transplantation procedures to drive market 306
14.4.5 SOUTH KOREA 311
14.4.5.1 Large transplant waiting population to drive market growth 311
14.4.6 REST OF ASIA PACIFIC 316
14.5 LATIN AMERICA 321
14.5.1 BRAZIL 327
14.5.1.1 Expanding transplant programs to drive market growth 327
14.5.2 MEXICO 332
14.5.2.1 Growing medical tourism to support market growth 332
14.5.3 REST OF LATIN AMERICA 337
14.6 MIDDLE EAST & AFRICA 342
14.6.1 UAE 348
14.6.1.1 Expanding organ donation programs to drive market growth 348
14.6.2 SAUDI ARABIA 353
14.6.2.1 Strengthening transplantation capabilities to support market growth 353
14.6.3 REST OF MIDDLE EAST & AFRICA 358
14.6.4 US: HEART, LIVER, AND LUNG TRANSPLANTS MARKET VOLUME 363
15 COMPETITIVE LANDSCAPE 364
15.1 INTRODUCTION 364
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 364
15.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN TRANSPLANT DIAGNOSTICS MARKET 364
15.3 REVENUE ANALYSIS, 2023–2025 366
15.4 MARKET SHARE ANALYSIS, 2025 366
15.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025 367
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 369
15.5.1 STARS 369
15.5.2 EMERGING LEADERS 369
15.5.3 PERVASIVE PLAYERS 369
15.5.4 PARTICIPANTS 369
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 371
15.5.5.1 Company footprint 371
15.5.5.2 Region footprint 371
15.5.5.3 Product & service footprint 372
15.5.5.4 Application footprint 372
15.5.5.5 End-user footprint 373
 
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 374
15.6.1 PROGRESSIVE COMPANIES 374
15.6.2 RESPONSIVE COMPANIES 374
15.6.3 DYNAMIC COMPANIES 374
15.6.4 STARTING BLOCKS 374
15.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 376
15.6.5.1 Detailed list of key startups/SMEs 376
15.6.5.2 Competitive benchmarking of startups/SMEs (1/2) 376
15.6.5.3 Competitive benchmarking of startups/SMEs (2/2) 377
15.7 COMPANY VALUATION & FINANCIAL METRICS 377
15.7.1 FINANCIAL METRICS 377
15.7.2 COMPANY VALUATION 378
15.8 BRAND/PRODUCT COMPARISON 378
15.9 COMPETITIVE SCENARIO 379
15.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS 379
15.9.2 DEALS 381
15.9.3 EXPANSIONS 384
16 COMPANY PROFILES 386
16.1 KEY PLAYERS 386
16.1.1 THERMO FISHER SCIENTIFIC INC. 386
16.1.1.1 Business overview 386
16.1.1.2 Products offered 387
16.1.1.3 Recent developments 391
16.1.1.3.1 Product & service launches 391
16.1.1.3.2 Deals 391
16.1.1.3.3 Expansions 392
16.1.1.4 MnM view 393
16.1.1.4.1 Right to win 393
16.1.1.4.2 Strategic choices 393
16.1.1.4.3 Weaknesses & competitive threats 393
16.1.2 F. HOFFMANN-LA ROCHE LTD. 394
16.1.2.1 Business overview 394
16.1.2.2 Products offered 395
16.1.2.3 Recent developments 397
16.1.2.3.1 Product launches & approvals 397
16.1.2.3.2 Deals 398
16.1.2.4 MnM view 398
16.1.2.4.1 Right to win 398
16.1.2.4.2 Strategic choices 398
16.1.2.4.3 Weaknesses & competitive threats 398
 
16.1.3 BIO-RAD LABORATORIES, INC. 399
16.1.3.1 Business overview 399
16.1.3.2 Products offered 400
16.1.3.3 Recent developments 403
16.1.3.3.1 Product launches 403
16.1.3.3.2 Deals 403
16.1.3.4 MnM view 404
16.1.3.4.1 Right to win 404
16.1.3.4.2 Strategic choices 404
16.1.3.4.3 Weaknesses & competitive threats 404
16.1.4 QIAGEN N.V. 405
16.1.4.1 Business overview 405
16.1.4.2 Products offered 406
16.1.4.3 Recent developments 410
16.1.4.3.1 Product launches & approvals 410
16.1.4.3.2 Deals 410
16.1.4.4 MnM view 411
16.1.4.4.1 Right to win 411
16.1.4.4.2 Strategic choices 411
16.1.4.4.3 Weaknesses & competitive threats 411
16.1.5 BIOMÉRIEUX 412
16.1.5.1 Business overview 412
16.1.5.2 Products offered 413
16.1.5.3 Recent developments 415
16.1.5.3.1 Product launches & approvals 415
16.1.5.3.2 Deals 415
16.1.5.4 MnM view 416
16.1.5.4.1 Right to win 416
16.1.5.4.2 Strategic choices 416
16.1.5.4.3 Weaknesses & competitive threats 416
16.1.6 ILLUMINA, INC. 417
16.1.6.1 Business overview 417
16.1.6.2 Products offered 418
16.1.6.3 Recent developments 420
16.1.6.3.1 Deals 420
16.1.7 BECTON, DICKINSON AND COMPANY 421
16.1.7.1 Business overview 421
16.1.7.2 Products offered 422
16.1.7.3 Recent developments 423
16.1.7.3.1 Deals 423
 
16.1.8 CAREDX, INC. 424
16.1.8.1 Business overview 424
16.1.8.2 Products offered 425
16.1.8.3 Recent developments 427
16.1.8.3.1 Product launches 427
16.1.8.3.2 Deals 428
16.1.9 DIASORIN S.P.A. 429
16.1.9.1 Business overview 429
16.1.9.2 Products offered 430
16.1.9.3 Recent developments 431
16.1.9.3.1 Product launches 431
16.1.9.3.2 Deals 432
16.1.10 WERFEN 433
16.1.10.1 Business overview 433
16.1.10.2 Products offered 434
16.1.10.3 Recent developments 435
16.1.10.3.1 Product launches 435
16.1.10.3.2 Deals 435
16.1.11 MERCK KGAA 436
16.1.11.1 Business overview 436
16.1.11.2 Products offered 437
16.1.11.3 Recent developments 438
16.1.11.3.1 Deals 438
16.1.11.3.2 Expansions 438
16.1.12 HOLOGIC, INC. 440
16.1.12.1 Business overview 440
16.1.12.2 Products offered 441
16.2 OTHER PLAYERS 442
16.2.1 EUROBIO SCIENTIFIC 442
16.2.2 BIOFORTUNA LIMITED 443
16.2.3 BAG DIAGNOSTICS GMBH 444
16.2.4 FUJIREBIO 445
16.2.5 HISTOGENETICS LLC 446
16.2.6 PACBIO 447
16.2.7 TBG BIOTECHNOLOGY CORP 448
16.2.8 SCISCO GENETICS, INC. 449
16.2.9 INNO-TRAIN DIAGNOSTIK GMBH 450
16.2.10 BIONOBIS 451
16.2.11 TAKARA BIO INC. 451
16.2.12 KRISHGEN BIOSYSTEMS PRIVATE LIMITED 452
16.2.13 PROIMMUNE LTD. 452
17 RESEARCH METHODOLOGY 453
17.1 RESEARCH DATA 453
17.1.1 SECONDARY DATA 454
17.1.1.1 List of secondary sources 454
17.1.1.2 Key data from secondary sources 455
17.1.2 PRIMARY DATA 455
17.1.2.1 List of primary sources 456
17.1.2.2 Key data from primary sources 456
17.1.2.3 Key industry insights 457
17.1.2.4 Breakdown of primary interviews 458
17.2 MARKET SIZE ESTIMATION 458
17.2.1 TOTAL MARKET SIZE: TRANSPLANT DIAGNOSTICS MARKET 458
17.2.2 BOTTOM-UP APPROACH 458
17.2.2.1 Approach 1: Revenue estimation of key players 459
17.2.2.2 Approach 2: Study of annual reports and investor presentations 459
17.2.2.3 Approach 3: Primary interviews 459
17.2.2.4 Growth forecast 460
17.2.2.5 CAGR projections 460
17.2.3 TOP-DOWN APPROACH 461
17.3 DATA TRIANGULATION 462
17.4 RESEARCH ASSUMPTIONS 463
17.4.1 STUDY-RELATED ASSUMPTIONS 463
17.5 STUDY ASSUMPTIONS 463
17.5.1 PARAMETRIC ASSUMPTIONS 464
17.5.2 GROWTH RATE ASSUMPTIONS 464
17.6 RESEARCH LIMITATIONS 464
17.7 RISK ASSESSMENT 465
18 APPENDIX 466
18.1 DISCUSSION GUIDE 466
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 480
18.3 CUSTOMIZATION OPTIONS 482
18.4 RELATED REPORTS 482
18.5 AUTHOR DETAILS 483